Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5114/aoms.2014.42571 http://scihub22266oqcxt.onion/10.5114/aoms.2014.42571 C4042041!4042041!24904652     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arch+Med+Sci 2014 ; 10 (2): 213-21 Nephropedia Template TP {{tp|p=24904652|t=2014. Second- versus first-generation drug-eluting stents for diabetic patients: a meta-analysis |pdf=|usr=}}{{24904652}} gab.com Text Second- versus first-generation drug-eluting stents for diabetic patients: a meta-analysis JO: Arch Med Sci http://www.kidney.de/pget.php?&tw=1&pmid=24904652 #FOAvip Introduction: The issue of whether various drug-eluting stents (DES) provide similar benefit in diabetic patients with coronary artery disease remains unclear. The purpose of the study is to assess the clinical utility of the second-generation and first-generation DES in patients with diabetes mellitus by a meta-analysis. Material and methods: A systematic literature search of PubMed, EMBASE, and Cochrane databases was conducted. We included randomized trials involving head-to-head comparison of clinical outcomes of second- versus first-generation DES in patients with a diagnosis of diabetes with at least 6-month follow-up data. Summary statistics were calculated using random-effects models. Results: A total of 10 trials with 4503 patients were available for analysis. The pooled analyses showed that the second-generation everolimus-eluting stent (EES) significantly lowered all-cause mortality (risk ratio (RR) = 0.58, 95% CI: 0.37?0.90; p = 0.01) and the risk of stent thrombosis (RR = 0.46, 95% CI: 0.22?0.95; p = 0.03) compared with the first-generation sirolimus-eluting stents (SES) and the overall first-generation DES, respectively. Moreover, the EES showed a tendency toward reducing the incidence of recurrent myocardial infarction when compared with paclitaxel-eluting stents (PES) (RR = 0.58, p = 0.08). In contrast, the second-generation zotarolimus-eluting stents (ZES) were associated with increased rates of stent thrombosis and risk of target lesion revascularization in comparison with the SES (both p < 0.05) or the overall first-generation DES (both p < 0.05). Conclusions: The second-generation EES are highly effective in reducing the risk of major cardiac events in diabetic patients with coronary artery disease. Twit Text FOAVip Second- versus first-generation drug-eluting stents for diabetic patients: a meta-analysis ????Arch Med Sci http://www.kidney.de/pget.php?&tw=1&pmid=24904652 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24904652 #FOAvip English Wikipedia <ref>{{Cite pmid|24904652}}</ref> Second- versus first-generation drug-eluting stents for diabetic patients: a meta-analysis #MMPMID24904652 Yan P; Dong P; Li Z Arch Med Sci 2014[May]; 10 (2): 213-21 PMID24904652show ga Introduction: The issue of whether various drug-eluting stents (DES) provide similar benefit in diabetic patients with coronary artery disease remains unclear. The purpose of the study is to assess the clinical utility of the second-generation and first-generation DES in patients with diabetes mellitus by a meta-analysis. Material and methods: A systematic literature search of PubMed, EMBASE, and Cochrane databases was conducted. We included randomized trials involving head-to-head comparison of clinical outcomes of second- versus first-generation DES in patients with a diagnosis of diabetes with at least 6-month follow-up data. Summary statistics were calculated using random-effects models. Results: A total of 10 trials with 4503 patients were available for analysis. The pooled analyses showed that the second-generation everolimus-eluting stent (EES) significantly lowered all-cause mortality (risk ratio (RR) = 0.58, 95% CI: 0.37?0.90; p = 0.01) and the risk of stent thrombosis (RR = 0.46, 95% CI: 0.22?0.95; p = 0.03) compared with the first-generation sirolimus-eluting stents (SES) and the overall first-generation DES, respectively. Moreover, the EES showed a tendency toward reducing the incidence of recurrent myocardial infarction when compared with paclitaxel-eluting stents (PES) (RR = 0.58, p = 0.08). In contrast, the second-generation zotarolimus-eluting stents (ZES) were associated with increased rates of stent thrombosis and risk of target lesion revascularization in comparison with the SES (both p < 0.05) or the overall first-generation DES (both p < 0.05). Conclusions: The second-generation EES are highly effective in reducing the risk of major cardiac events in diabetic patients with coronary artery disease. äSecond- versus first-generation drug-eluting stents for diabetic patie(epmc).pdf DeepDyve Pubget Overpricing